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Objectives: To report the extent and components of global efforts in antimicrobial stewardship (AMS) in hospitals.
Methods: An Internet-based survey comprising 43 questions was disseminated worldwide in 2012.
Results: Responses were received from 660 hospitals in 67 countries: Africa, 44; Asia, 50; Europe, 361; North
America, 72; Oceania, 30; and South and Central America, 103. National AMS standards existed in 52% of coun-
tries, 4% were planning them and 58% had an AMS programme. The main barriers to implementing AMS pro-
grammes were perceived to be a lack of funding or personnel, a lack of information technology and prescriber
opposition. In hospitals with an existing AMS programme, AMS rounds existed in 64%; 81% restricted antimicro-
bials (carbapenems, 74.3%; quinolones, 64%; and cephalosporins, 58%); and 85% reported antimicrobial usage,
with 55% linking data to resistance rates and 49% linking data to infection rates. Only 20% had electronic pre-
scribing for all patients. A total of 89% of programmes educated their medical, nursing and pharmacy staff on
AMS. Of the hospitals, 38% had formally reviewed their AMS programme: reductions were reported by 96% of
hospitals for inappropriate prescribing, 86% for broad-spectrum antibiotic use, 80% for expenditure, 71% for
healthcare-acquired infections, 65% for length of stay or mortality and 58% for bacterial resistance.
Conclusions: The worldwide development and implementation of AMS programmes varies considerably. Our
results should inform and encourage the further evaluation of this with a view to promoting a worldwide stew-
ardship framework. The prospectivemeasurement of well-defined outcomes of the impact of these programmes
remains a significant challenge.
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Introduction
Antimicrobial resistance is growing and the pipeline for new anti-
biotics is running dry.1,2 This is especially a problem with multire-
sistant Gram-negative bacteria.1 Two main approaches are
suggested to address this problem, namely an investment in
new antibiotic discovery and improved antimicrobial stewardship
(AMS).1–3 The earliest described organized AMS activities go back
to the early 1970s.4 The term ‘antimicrobial stewardship’ was first
coined in 1997 as describing a collection of strategies, policies,
guidelines or tools that could improve antimicrobial prescribing
with the aim of decreasing antimicrobial resistance and use.5
Many definitions have been suggested for AMS across the world,
but agreement has not been reached on one definition. While
studies to investigate AMS have previously been undertaken, the
vast majority have only been conducted on a national scale (e.g.
in the USA,6,7 the UK8 and Belgium9) and good quality information
from all continents is lacking. Nonetheless, all the studies to date
describe varying levels of maturity of stewardship, different prior-
ities or strategies and a different impact on measured outcomes.
A European survey of 32 countries10 focused around hospital anti-
biotic consumption and information about the presence of pol-
icies and practices again revealed much variation across
countries. The aim of this global cross-sectional survey was to
investigate the depth and penetration of AMS across the world.
The survey collected outcome data for the relevant strategies
# The Author 2014. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved.
For Permissions, please e-mail: journals.permissions@oup.com
J Antimicrob Chemother 2015; 70: 1245–1255
doi:10.1093/jac/dku497 Advance Access publication 18 December 2014
1245
employed and information about the main perceived barriers
found in different regions. Learning about these barriers and facil-
itators for stewardship may identify opportunities for improving
practice globally.
Methods
In March 2011, the ESCMID Study Group for Antibiotic Policies (ESGAP)
launched a global survey of AMS. To achieve worldwide coverage, agree-
ment was reached to form a joint working party with the AMS group of
the International Society of Chemotherapy (ISC).
A literature search was undertaken of published standards and surveys
on AMS using Medline, Embase and Google Scholar (articles published in
English). Search termswere ‘antimicrobial’ or ‘antibiotic’ and ‘stewardship’
or ‘control’.5,11–49 The working party also shared surveys not identified
within the literature search.
From the literature, a draft questionnaire was developed using the
components of AMS that had been identified, and from questions asked
in other surveys that would capture the breadth of activities under-
taken.7,10,50 –60 Published recommendations for the development and
implementation of web-based surveys were applied prospectively to the
design of our research survey.61–63
A web-based survey tool (SurveyMonkeyw) was used. The initial survey
was distributed in October 2011 to key opinion leaders in AMS in all six con-
tinents to test the readability and clarity of the questions, especially in
countries where English was not themain language, and to reach consen-
sus on the questions. It was decided to restrict the survey to hospital AMS
activities and exclude ambulatory care.
The survey was piloted in 11 countries in six continents.63,64 The final
survey was 18 pages long with 45 questions (the questionnaire is available
as Supplementary data at JAC Online). In order to decrease the time taken
to complete the survey, it used page and question logic that missed out
pages or questions asking for more information depending on the answers.
An invitation letter was sent to regional and country contacts within
the ISC and ESCMID for distribution via their infectious diseases, microbiol-
ogy and antimicrobial pharmacy networks for each continent and country
in March 2012. Further advertising took place during the 2012 ECCMID
conference, through newsletters and the use of Twitter and other infection-
related intranet sites. An interim review of data in April 2012 identified
limited penetration to the African, Asian and South American continents.
It was agreed to extend the original 5 week collection period to 6 months
from March to September 2012 to maximize the response rate.
Only one IP address was allowed per hospital, but the survey could be
accessed again to update the answers if not all the information was com-
plete at the time of entry.
Descriptive data analysis was undertaken using IBM SPSS version 19
(Chicago, IL, USA). Duplicates were identified by duplicate hospital
names and addresses. Where there were duplicate entries, these were
amalgamated. Due to the size and complexity of the questionnaire, it
was decided to use all entries that contained information about AMS activ-
ities, even if there were missing answers for some questions.
Results
There were 722 survey returns but 62 entries had to be excluded:
10 did not record any demographic information and 52 were
duplicated entries from the same hospital. Therewere 660 eligible
responses (67 countries from six continents): Africa, 44; Asia, 50;
Europe, 361; North America, 72; Oceania, 30; and South America,
103 (Table 1). A total of 507/660 (77%) hospitals fully completed
the questionnaire. Tertiary teaching hospitals accounted for 48%
(319/660) of the returns, district or general hospitals for 24%
(161/660) and community or private (not state-funded) hospitals
for 8% (56/660) each. Hospitals with up to 500 overnight beds
accounted for 48% (314/660), those with 501–1000 beds for
33% (217/660) and those with over 1000 beds for 20% (129/
660) of the total.
AMS standards and structures
National AMS standards existed in 52% (35/67) of the countries,
and a further 4% (3/67) planned to introduce them. Of the hospi-
tals, 58% (367/636) had a local AMS programme with a median
duration of 3 years and 22% (143/636) planned to introduce
one. The AMS programmes of European hospitals had been run-
ning longer (Table 2).
Although the majority of hospitals reported the existence of
drug and therapeutic committees (85%, 543/637), only 62%
(396/637) had a specific AMS committee, with variation across
the continents: from 12% (5/43) in Africa to 77% (267/348) in
Europe. A total of 46% (293/637) of hospitals reported a specific
overarching AMS strategy or code of practice. Only 38% (232/616)
published an annual report on AMS and 29% (179/612) had a pub-
lished AMS work plan.
AMS programme objectives, resources and barriers to
effective implementation
Hospitals were asked the three main objectives of their AMS
programmes. Reducing antimicrobial resistance was themost fre-
quent reason across all continents. Improving patient outcomes,
reducing antimicrobial prescribing, reducing Clostridium difficile
infections and other healthcare-acquired infections and then
Table 1. Summary of validated returns by continent
Africa,
n (%)
Asia,
n (%)
Europe,
n (%)
North America,
n (%)
Oceania,
n (%)
South and Central
America, n (%) Total, (n)
Number of countries returning
questionnaires
10 (15) 14 (20) 26 (38) 5 (7) 2 (3) 12 (17) 67a
Hospital returns by continent 44 (7) 50 (8) 361 (55) 72 (11) 30 (5) 103 (16) 660
Mean hospital returns by
country (range)
4 (1–13) 3 (1–9) 12 (1–104) 15 (1–35) 15 (13–17) 7 (1–39) 8 (1–104)
Median hospital returns by country 2 2 8 9 15 4 3
aRussia and Turkey had hospitals in both Europe and Asia.
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reducing costs were the next reasons, with a variation in the order
by continent.
The resources available for AMS programmes varied by contin-
ent (Table 3). In Asia, Europe, North America and Oceania, the
main manpower was antimicrobial or infectious diseases phar-
macists, but stewardship was delivered by infection control staff
in Africa. The main medical input was by infectious diseases doc-
tors in most continents except for Africa and Europe, where med-
ical microbiologists predominated.When asked about the funding
of specific posts within the AMS programmes, 81% (820/1008) of
posts were funded from general or hospital department budgets,
15% (150/1008) from dedicated funding [the highest proportion
being antimicrobial or infectious diseases pharmacists—21%
(61/292 posts)], and 4% (38/1008) of all AMS staff were funded
from savings.
Figure 1 shows the top three barriers to delivering a functional
and effective AMS programme in hospitals at the current time.
These were a lack of funding or personnel and a lack of informa-
tion technology or ability to get data, followed by prescriber
opposition or other higher priorities. This was uniform across all
continents except for Africa, which ranked information technology
as the primary issue. In the 143/636 hospitals (22%) that planned
to develop an AMS programme, the main barrier was lack of fund-
ing, except in South America, where a lack of awareness on the
part of the hospital administration was the main reason stated.
AMS strategies
Various strategies were employed to deliver AMS (Table 4). Most
hospitals throughout the world had specific guidance on the
treatment of infections and on prophylaxis for surgical site infec-
tions, but there were marked differences for the authorization of
restricted antibiotics—38% (5/13) in Asia compared with up to
88% in Europe (224/255). Advice by telephone was available
from infectious disease ormicrobiology specialists but their advice
was less available on ward rounds. The routine follow-up of
patients with bacteraemia occurred more commonly in Oceania
than the other continents. North America used Day 3 reviews,
guidance on intravenous-to-oral switching, automatic stop or
review policies and pharmacist pre-authorized to optimize the
Table 2. Summary of AMS standards and programmes
Africa,
n/N (%)
Asia,
n/N (%)
Europe,
n/N (%)
North America,
n/N (%)
Oceania,
n/N (%)
South and Central
America, n/N (%)
Total,
n/N (%)
Country AMS standards 2/10 (20) 5/12 (42) 21/26 (81) 1/5 (20) 1/2 (50) 5/12 (42) 35/67 (52)
Country AMS standards
in preparation
0/10 (0) 1/12 (8) 1/26 (4) 0/5 (0) 0/2 (0) 1/12 (8) 3/67 (4)
Regional AMS standards 3/32 (9) 6/38 (16) 120/279 (43) 8/56 (14) 11/30 (37) 21/69 (30) 169/504 (34)
Hospital AMS standards 9/42 (21) 29/46 (63) 246/339 (73) 30/65 (46) 16/33 (48) 46/85 (54) 376/610 (62)
AMS programme in place 6/43 (14) 26/49 (53) 230/348 (66) 45/67 (67) 16/34 (47) 44/95 (46) 367/636 (58)
AMS programme in planning 10/43 (23) 14/49 (29) 70/348 (20) 15/67 (22) 10/34 (29) 24/95 (25) 143/636 (22)
Median duration of AMS
programme (years)
1 3 5 3 2 3 3
Table 3. Average AMS programme resource hours per week, n¼337
Africa
(n¼12)
Asia
(n¼25)
Europe
(n¼190)
North America
(n¼49)
Oceania
(n¼14)
South and Central
America
(n¼44) Mean
Antimicrobial or infectious diseases
pharmacist (n¼320)
6 13 18 32 17 9 18
Infectious diseases doctor (n¼284) 3 8 8 15 6 12 10
Medical microbiologist (n¼308) 8 6 11 5 1 7 9
Infection control staff (n¼220) 9 9 8 6 1 8 8
Nurse (n¼199) 8 7 3 4 0 14 6
Administrative support (n¼202) 4 6 2 6 2 7 4
Data analyst (n¼201) 5 2 3 9 2 5 4
Other pharmacist (n¼199) 8 3 2 7 0 9 4
Doctors in training (n¼188) 5 3 3 5 8 4 4
Other medical specialty (n¼199) 5 5 2 1 0 8 3
Pharmacy technician (n¼188) 4 2 2 1 0 8 3
Scientist or laboratory staff (n¼179) 7 3 1 2 0 7 3
Surgeon (n¼201) 4 5 1 1 0 3 2
Antimicrobial stewardship worldwide survey
1247
JAC
dose more often than elsewhere in the world. Care bundles (e.g.
for community- or ventilator-acquired pneumonia) were quite fre-
quently used inmost hospitals across all continents except Europe
and Oceania. Interventions used less often were separate anti-
microbial prescriptions, the measurement of inflammatory mar-
kers such as procalcitonin to avoid starting antibiotics or
facilitate stopping antibiotics earlier, restricting the access of
pharmaceutical representatives and the cycling of antibiotics.
AMS rounds existed in 64% (261/408) of hospitals. Intensive
care ward rounds were the most common in 74% (290/390) of
hospitals and mostly occurred daily, followed by ward rounds on
medical wards in 68% (248/366, mainly weekly), surgical wards in
63% (232/370,mainlyweekly), paediatric wards in 43% (143/335,
less than weekly) and less often emergency departments in 35%
(120/345, less than weekly). The content of the antimicrobial
guidelines (n¼402) varied considerably. Most of the guidelines
contained dosages (89%), alternatives for antimicrobial allergy
(88%), preferred route (86%), duration of treatment (79%), guid-
ance on intravenous-to-oral switching (70%), dosing in renal or
liver impairment (60%) or diagnosis (60%). Less commonly cov-
ered were investigations (46%), guidance on directed therapy or
a revision of therapy (43%), costs (24%) and dosing in obesity
(23%). Some provided guidelines for antifungal (55%) and anti-
viral (38%) agents. Few hospitals could monitor guideline use
(35%) or allow feedback direct from the guideline (38%). Most
treatment guidelines were updated annually (41%) but guidance
on surgical prophylaxis was most commonly updated every 2
years (38%). The antimicrobial formulary and restricted lists
were usually updated annually.
Most hospitals (81%, 329/406) restricted some antimicrobials:
73% (282/384) restricted carbapenems, 64% (246/385) quino-
lones and 58% (223/383) cephalosporins. A post-prescription
review of restricted antimicrobials by the pharmacy departments
was carried out in 64% (219/340) of hospitals. A total of 31%
(106/342) restricted before the first dose in all areas, 25% (87/
342) restricted outside intensive care and 41% (132/319) restricted
after the first dose, and only a few hospitals had no restrictions.
Only 20% (102/516) had electronic prescribing for all their patients
and a further 16% (80/516) had limited electronic prescribing. In
the e-prescribing systems used, 51% (83/163) mandated the dur-
ation and 35% (56/160) mandated the indication. Approval for
restricted antibiotics was required in 46% (72/158) of systems.
Electronic patient records existed for all or some patients in
43% (213/491). Few hospitals had full or limited automated anti-
microbial dispensing (15%, 73/481) or data warehouse surveil-
lance systems that linked prescribing to the laboratory results
(17%, 78/458). Full or limited dispensing of antimicrobial agents
to individual patients occurred in only 34% (163/480) of hospitals.
Barriers to delivering a functional and effective AMS programme
Current AMS
programme (763)
Planned AMS
programme (348)
Lack of
personnel
or funding,
n (%)
Other higher
priority
initiatives,
n (%)
Administration
not aware of
AMS
programme,
n (%)
Opposition
from
prescribers,
n (%)
Lack of
information
technology
support and/or
ability to get
data, n (%)
No
barriers,
n (%)
Current
AMS
programme
(763)
219 (29) 118 (15) 68 (9) 128 (17) 175 (23) 55 (7)
Planned
AMS
programme
(348)
100 (29) 69 (20) 48 (14) 43 (12) 57 (16) 31 (9)
29% 29%
15% 20%
9%
14%
17%
12%
23% 16%
7% 9% No barriers
Lack of information technology
support and/or ability to get data
Opposition from prescribers
Administration not aware of AMS
programme
Other higher priority initiatives
Lack of personnel or funding
Figure 1. Barriers to delivering a functional and effective AMS programme.
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Communication
The intranet was the most common method of communication,
followed by booklets, email, posters and then newsletters. There
were, however, differences across the continents, with Africa and
South America preferring booklets and staff meetings rather than
an intranet. There was little use of newer technologies such as
smartphone applications or screensavers.
Evaluation of interventions: process and outcomes
Antimicrobial audit was undertaken in 80% (312/390) of hospi-
tals. The most frequently undertaken audits were documentation
of the indication for (66%, 228/344) and the duration of prescrip-
tion (64%, 212/332) and compliance with infection care bundles
(56%, 158/282), whichwere generally donemonthly. Other audits
were carried out mainly annually; these covered compliance with
guidelines (74%, 253/341), audits of guidelines for surgical site
infection (71%, 234/330) and aminoglycoside/glycopeptide level
monitoring (51%, 163/318). Important audits undertaken less
oftenwere: time to first dose in severe sepsis (35%, 101/292), out-
come of the Day 3 reviews (43%, 136/313) or cultures that were
taken before antibiotics were given (41%, 121/295). Most special-
ties (58%, 160/278) never audited their own practice but relied on
external audits. Two-thirds of respondents undertook point preva-
lence surveys (68%, 221/323).
Antimicrobial usage was monitored by 85% (334/391) of hos-
pitals. Most reported expenditure (82%, 290/353), DDDs (80%,
251/315) and DDDs/occupied bed days (67%, 215/319) at hos-
pital level but less so at specialty level [65% (206/317), 57%
(180/315) and 53% (162/308), respectively]. A total of 55%
(170/307) linked usage to resistance rates and 49% (146/299)
linked usage to infection rates.
Of the 38% (119/317) of hospitals that formally assessed their
AMS programme for return on investment or economic viability,
most reported reductions in inappropriate prescribing (96%,
77/80), use of broad-spectrum antibiotics (86%, 83/96), direct
expenditure (80%,70/87) and healthcare-acquired infections
(71%, 47/66). A total of 65% (26/40) declared a reduction in
length of stay or mortality and 58% (39/67) a reduction in anti-
microbial resistance. Of the 270 hospitals that had assessed the
impact of AMS ward rounds, 121 (45%) reported a reduction in
antimicrobial consumption, and 41 (15%) an increase, with the
largest impact on reduction in consumption being seen on surgi-
cal wards.
Education
Most hospitals (89%, 356/400) educated their healthcare staff.
Overall, 96% of hospitals educated their senior and trainee doc-
tors. Doctors most commonly received face-to-face training
Table 4. AMS strategies—all or some wards (actual or planned AMS programme), n¼422
Asia
(13) (%)
Africa
(31) (%)
Europe
(258) (%)
North America
(54) (%)
Oceania
(23) (%)
South America
(43) (%)
Total
(422) (%)
Treatment guidelines 85 84 98 89 96 84 94
Surgical prophylaxis guidelines 77 94 95 87 96 88 93
Approved antibiotics (formulary) 69 84 95 87 91 77 90
Reserve antibiotics needing authorization
by indication
38 84 88 87 87 77 84
Infectious diseases/microbiology advice
by telephone
85 84 92 81 96 84 89
Infectious diseases/microbiology advice
on ward rounds
69 87 84 63 74 81 81
Systematic advice for bacteraemia by infectious
diseases/microbiology
46 74 78 52 83 74 73
Dose optimization on request 92 71 80 87 96 67 80
Intravenous-to-oral switch guidance 62 65 82 91 78 67 80
Review of intravenous therapy at Day 3 62 61 78 89 61 70 76
Care bundles (e.g. ventilator) 85 90 59 76 30 72 64
Automatic stop/review policy 23 58 42 69 43 40 46
Pre-authorized pharmacy-driven dose optimization
(e.g. automatic renal dose adjustments,
intravenous-to-oral conversions etc.)
31 48 36 69 35 47 42
Separate antimicrobial chart or section 62 55 40 33 0 47 39
Inflammatory markers to prevent initiation of
antibiotics, e.g. procalcitonin
69 65 37 22 13 51 39
Inflammatory markers to stop antibiotics early, e.g.
procalcitonin
46 58 35 24 13 51 36
Restrictions on access by pharmaceutical
representatives
31 45 26 56 43 40 33
Antibiotic cycling programme 23 19 14 11 4 42 17
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(trainees, 68%; and seniors, 46%) or written information (45%
and 35%, respectively) at induction. Short courses were provided
for trainees (31%) and seniors (27%). A small number of hospitals
did not educate senior doctors (6%) or trainee doctors (2%). Fewer
than 25% had mandatory updates every 1 or 2 years.
Nurses received less education; 27% received face-to-face
training and/or 16% were given written information at induction,
21% undertook short courses and 15% received no specific edu-
cation. Only 12% received mandatory updates.
Most pharmacists (94%) were educated, mainly at induction:
43% by face-to-face training and/or 25% by written information
and 22% by short courses. Few centres (17% or fewer) used
e-learning across the different staff groups.
Discussion
We present here data describing AMS practice in 660 hospitals
in 67 countries across six continents. Our findings show a signifi-
cant diversity and variation across the continents in relation to the
organizational structures, range of interventions and impact
of AMS programmes in hospitals. There were, however, some
consistent approaches to AMS, especially across more developed
countries.
Our survey has several limitations. First, respondents were self-
selecting and there was no method of validating their data entry.
Additionally, recruitment often occurred through contact sources
of the authors or through their professional associations, thereby
further contributing to a potential recruitment bias. Second, the
interpretation of the questions and definitions used may not
always have been clear or consistent between countries. For
example, somemay have no relevance or meaning in a local con-
text, although help was available by email to minimize this bias.
Third, there was an imbalance between the continents in terms
of reporting results. The number of returns from Oceania and
North America is clearly low and under-representative of signifi-
cant and in some cases mature stewardship activity in these con-
tinents. Although the number of returns from Oceania and North
Americawas low, these sorts of difference are inherent in this type
of survey, especially where there is a country-wide invitation.
A comparison to recently published AMS surveys from these
countries demonstrated some consistencies and variation. An
Australian state-wide survey of 155 hospitals undertaken in
201165 showed similar results for the existence of treatment
guidelines but significantly lower rates for restriction and formu-
laries. A 2009 survey of 406 USA hospitals6 reported a lower rate
of AMS programmes in place, antimicrobial restriction and guide-
lines for intravenous-to-oral switching but reported similar results
for the type of staff delivering their AMS programmes and access
to an infectious diseases specialist to review the patient. Europe
accounted for more than half of the returns, and England for
15% of hospital returns. The impact of the data from England
on those from Europe did not, however, cause significant changes
in our results. For example, if the English data were removed from
our analyses, the most important modifications would be a 7%
reduction in AMS programmes in place but no difference in dur-
ation. Similarly, antimicrobial pharmacist time would decrease
from 17 to 8 hours per week, and medical microbiologist input
from 11 to 7 hours. Wewould observe a reduction in antimicrobial
audit activity (from 82% to 71%) and a restriction of cephalospor-
ins (from 66% to 46%) and to a lesser degree fluoroquinolones
(from 72% to 61%). Therefore, we do not consider that the high
participation of English hospitals represents a significant bias.
Finally, this was a large-scale survey of institutions and we were
unable to unravel or explore local circumstances, e.g. whether
hospital policies had been adapted for the local setting or
reflected regional or national antimicrobial resistance patterns.
Prescribing will depend upon the hospital case mix and local
experience with pathogens, which will be reflected in recommen-
dations for empirical and definitive therapies. Another limitation is
the proportion of respondents that completed the questionnaire
to the end. Most continents achieved a 78%–83% completion
rate. The outliers were Africa (89%, 39/44) and South America
(59%, 61/103).
Regardless of these caveats, the study provides us with some
important findings on standard approaches to AMS that are worth
highlighting. While 52% of the countries had national AMS stan-
dards, therewas a large variation across the continents: from81%
in Europe down to 20% in Africa and North America. There were
also few countries that were planning to introduce AMS stan-
dards—mainly those in Asia. This may reflect the continental
approach to antimicrobial resistance66 and the size of the coun-
tries involved. To achieve more effective clinical engagement for
stewardship in countries where national stewardship standards
already exist, the recent development of national clinical steward-
ship standards for Australian hospitals67 signifies possibly a
mature and natural evolutionary process for the implementation
of more effective stewardship in daily routine clinical care. These
data suggest that there is still much to do to deliver the WHO
Antimicrobial Resistance (AMR) strategy from 200168 and
201269 in which national AMS standards or guidelines are a core
recommendation. As for AMS standards within hospitals, Europe
again had the highest proportion, at 73%, followed by Asia and
South America, whereas Africa had the lowest. This presumably
reflects the relatively early stages of development of stewardship
as a core activity for combating AMR within African hospitals.
There is, however, evidence of emerging activity to address this
in Africa through a collaborative approach with infection preven-
tion teams70,71 Such an approach has been commended in other
systems as well.72
Two-thirds of the hospitals in North America and Europe had
AMS programmes. This probably reflects strong and historical
leadership on AMS from infectious diseases or microbiology orga-
nizations in the USA12 and Europe.73 The low- or middle-income
countries (Africa and South America) had lower levels of AMS pro-
grammes, which may reflect the lack of infrastructure in these
continents and a more recent political commitment.74 Despite
this variation, it is encouraging that stewardship programmes
are being developed, and are successful, as in Vietnam,75 or are
being promoted as a key policy recommendation as in India:
‘The Chennai Declaration’ recommendations of ‘A roadmap to
tackle the challenge of antimicrobial resistance’.76
There has been little investigation in the literature into the bar-
riers to the provision of AMS programmes. A review of barriers to
AMS programmes,17 an Australian study67 and two American stud-
ies6,50 have concurred that lack of finance is the major obstacle,
and the reported drivers matched those found in our global study.7
Most hospitals had a drug and therapeutics committee, but it
wasmainly European and North American hospitals that had AMS
committees. AMS policies and strategies were in place in fewer
than half of all hospitals, and even fewer published an annual
Howard et al.
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AMS report. Currently, the WHO has a Strategic and Technical
Advisory Group on antimicrobial resistance aiming to provide
stronger leadership to improve this situation.77 The type of staff
delivering AMS activities seems to reflect the staffing within
the healthcare system of that country. North America78 and
Oceania57 primarily deliver their AMS service with specialist phar-
macists and infectious disease specialist doctors whereas in
Europe the delivery is mixed, mainly with pharmacists8 and either
medical microbiologists (UK and Ireland79) or infectious disease
specialists80 on mainland Europe. The skill mix of the stewardship
team also reflects in the AMS strategies being delivered. For
example, pharmacist skills are often deployed to optimize
dosing, implement intravenous-to-oral switching or support post-
prescription review, while infectious disease specialists are pivotal
for ward rounds and diagnostic input.81 The role of themicrobiol-
ogy laboratory and the medical microbiologist is fundamental to
AMS, particularly through the interpretation, selective processing
and reporting of culture and susceptibility results.82 – 84 As
laboratories move towards centralization and increasing effi-
ciency, there is a real danger that specimens and culture results
will no longer be interpreted by experts and that data will simply
be reported without qualification to inexperienced clinicians,
leading to overtreatment. There appears to be infrequent use
of certain diagnostic or prescribing interventions that have
been shown to reduce the volume of antimicrobial prescribing
or improve patient outcomes, for example measurement of pro-
calcitonin,85 electronic prescribing with decision support or data
warehousing.16 On the other hand, AMS ward rounds were fre-
quently used, particularly in low- or middle-income countries.
Where their impact had been evaluated, there was about a
40% reduction in antimicrobial use.86–88
A restriction of broad-spectrum antibiotics was reported to
occur routinely, often combined with a post-prescription review.
The latter is generally regarded as a resource-intensive interven-
tion but a key clinical and cost-effective intervention, particularly
when linked to audit and feedback.89 The focus on optimizing the
use of certain antibiotic classes has been especially appealing,
with a significant impact on resistance16,90,91 and C. difficile infec-
tion rates.92 Formal antibiotic diversity strategies were infrequently
reported despite emerging evidence of their effectiveness in units
with high levels of antimicrobial resistance.93 Antibiotic cycling
strategies were also infrequently reported, possibly reflecting the
practical difficulties in doing this, including heavy resource use
and a scarcity of evidence to support cycling as an effective
means of controlling resistance.94,95
Audit and feedback is a core intervention in AMS. There is grow-
ing evidence that a regional or country-wide standardized
approach can show sustained improvements in acute medical
admission units in terms of both compliance with guidelines as
well as prophylaxis for surgical site infections.96 Outside measur-
ing compliance with antibiotic treatment, however, or the dur-
ation and indication of treatment for inpatients or prophylaxis
bundles, this approach did not frequently occur. Surprisingly,
over half of all specialties never audited their own practice. This
suggests that the significant impact of audit and feedback as a
stewardship and educational tool is underestimated. A recent
Cochrane review16 supported its value, particularly in the context
of a low baseline performance, when the source of feedback is a
supervisor or colleague, when it is providedmore than once, when
it is delivered in both verbal and written formats, and when it
includes both explicit targets and an action plan.97 Therefore,
this more focused evidence-based approach to feedback should
be more widely commended. Additionally, the collection and
feedback of consumption data is recommended,12 as the engage-
ment of prescribers is essential for antimicrobial management
teams to make any impact.98 Consumption metrics are a com-
monly used indicator of stewardship activity. Antimicrobial
usage was monitored by most hospitals with an AMS programme
as DDDs or expenditure, but fewer than half linked it to infection or
resistance rates. In order to demonstrate positive outcomes of
AMS programmes, there need to be improvements in the reporting
of antimicrobial usage, and preferably benchmarking between
similar hospitals.99,100 Using such data for benchmarking is, how-
ever, subject to many difficulties.
Whilemost hospitals provided AMS education, it was generally to
doctors in training or to pharmacists at induction and with written
materials. Nurses, however, appeared to receive little training des-
pite their critical role in the monitoring and administration of treat-
ment. The potential beneficial role of nurses in stewardship is
underestimated.101,102A competency- andoutcomes-based educa-
tional framework for stewardship is useful in planning suchan imple-
mentation of stewardship education.100,103 Few hospitals reported
using e-learning and most did not mandate updates. Without a
change in our education of prescribers and those who administer
or monitor antibiotics, AMS will remain challenging.17,102,104
Overall, those hospitals that had carried out a formal evalu-
ation of their AMS programme reported significant reductions in
inappropriate prescribing, primarily the use of broad-spectrum
agents, and a reduction in direct expenditure and healthcare-
acquired infections, as well as to a lesser extent in the length of
stay or mortality, and antimicrobial resistance. Respondents
were not, however, asked to provide references to published
reports and we acknowledge the limitations of self-reporting.
These findings are nevertheless consistent with the litera-
ture16,81,91,105,106 and argue for mandatory AMS programmes to
be implemented worldwide. The model for AMS programmes
and their implementation should offer flexibility to account for
the local healthcare structure, geography, culture and resources,
and could use published validated quality indicators.18,105,107 The
importance of measuring the impact of stewardship on outcomes
has recently been emphasized with the competition for scarce
financial resources, a key barrier identified in the survey.104 We
did not collect such outcome data, but large multicentre surveys
exploring the relationships between different stewardship activ-
ities and outcomes (mostly antibiotic use and resistance data)
are urgently needed. This could potentially facilitate prioritization
from amenu of stewardship activities in resource-limited settings.
The results of this survey showed the depth of AMS across the
world and the benefits that hospitals have reported from running
an AMS programme. It also demonstrated that there has been
some improvement in the implementation of AMS strategies com-
pared with some of the more recent AMS surveys carried out in
Europe in 2003,10 Australia in 201265 and the USA in 2009,6
200352 and 1998.108 We are unaware of published continent-
wide surveys in Asia, Africa or South America74 but one is currently
being undertaken in Asia.109 We hope that this work will inform
local and international policy-makers about current stewardship
activity and challenges with a view to fostering broader inter-
national collaboration as recommended by the recentWHO report
on resistance.110
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Practical impact of our findings and recommendations
Based on our findings, we would advocate: (i) an international
AMS framework; (ii) international evidence-based AMS interven-
tions/programmes; and (iii) mandatory public reporting of AMS
process and outcome measures.
In summary, the development and implementation of AMS
programmes varies considerably across theworld. The study high-
lights the need to better understand current practices globally,
not only in hospitals, but across all healthcare systems; this
should include ambulatory care, for which such data are scarce.
Our results should inform and encourage a further evaluation of
this with a view to promoting aworldwide stewardship framework
that is relevant to the context of the healthcare system, culturally
pertinent and, above all, flexible and dynamic to meet the needs
of the population. The prospective measurement of clear, well-
defined outcomes of the impact of these programmes clearly
remains a significant challenge if we are to persuade policy-makers
and funders of the added and long-term clinical effectiveness and
cost-effectiveness of these interventions aimed at combating anti-
microbial resistance.
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